Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Emer Leahy is Director at Pasithea Therapeutics. OQRO lists 3 transactions filed with the SEC under this name, the latest on Jul 20, 2026, each linked to the official Form 4.
Director
Disclosures on record
3
Companies involved
2
Jul 16, 20265,500disclosed Jul 20
DetailsOfficial recordPasithea TherapeuticsKTTA
2 disclosures · Dec 2025 – May 2026
May 1, 2026153Kdisclosed May 5
DetailsOfficial recordNov 28, 202533Kdisclosed Dec 1
DetailsOfficial recordOn the latest SEC Form 4, dated Nov 28, 2025, Emer Leahy reported holding 33,333 shares of Pasithea Therapeutics (KTTA). At the last close of $0 on Nov 17, 2026, that is about $14K. This is the stake disclosed in filings, not a net worth.
As of the latest filing on , Emer Leahy reported holding 33,333 shares of Pasithea Therapeutics (KTTA), worth about $14K at the last close of $0 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Pasithea Therapeutics KTTA | 33,333 | 33K direct | $0 | $14K | Nov 28, 2025 |
Is this Emer Leahy’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.